Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pharmaceutical SYNthesis BioVentures and AdAlta Collaborate to Enhance Cancer Immunotherapy

SYNthesis BioVentures and AdAlta Collaborate to Enhance Cancer Immunotherapy

9th April 2024

SYNthesis BioVentures and AdAlta, an Australia-based medical technology firm that specialises in the development of protein-based therapeutics, have signed a mutual agreement (MOU) to further analyse AdCella, a cancer therapeutic developed from a partnership between the two firms.  

The collaboration looks to improve cellular immunotherapies and tackle the difficulties associated with treating solid tumours.  

After the successful procurement of assets, AdAlta will possess a significant stake in AdCella, while SYNBV BioVentures will retain 25% until the subsequent funding phase.  

Tim Oldham, the head executive at AdAlta, stated, “As part of our stated strategy to expand our clinical-stage pipeline with assets that work with our i-body platform, we have identified a unique and exciting opportunity to bring highly innovative cellular immunotherapies to Australian patients.” 

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved. 

We currently have 8 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.